Management of patients with low-grade follicular lymphoma.
Cabanillas
F F
FF
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002883:Chromosomes, Human, Pair 14; D002887:Chromosomes, Human, Pair 18; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000032:analysis; D004259:DNA-Directed DNA Polymerase / Q000032:analysis; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008224:Lymphoma, Follicular / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D014178:Translocation, Genetic; D014750:Vincristine / Q000627:therapeutic use
D004273:DNA, Neoplasm; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007372:Interferons; D004259:DNA-Directed DNA Polymerase; D011241:Prednisone